Fundraising Fox
Access Biotechnology
Corporate VCAnAccess Industriesbiotech investment arm
New York · Seed–Late Stage · 3 people tracked
Find your way into Access Biotechnology
Sign up to see every warm intro you have to Access Biotechnology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Access Biotechnology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Access Biotechnology invests in transformative therapies addressing conditions with high unmet need across therapeutic areas, modalities, and development stages, from discovery-stage platforms to late-stage clinical programs, spanning both private and public biopharma companies. Operating without the constraints of a typical venture fund cycle, the firm takes a long-term orientation, aiming to build and support portfolio companies over time. It emphasizes flexibility, deep technical and scientific rigor grounded in medical expertise, and a collaborative partnership style with founders, management, and co-investors. The firm prioritizes fundamental value creation—investing in people, data, and innovation rather than momentum or hype—believing financial returns will follow the value created for patients and society.
Source: firm website, verified Sep 27, 2026.
Team · 3 people
from the firm's website & public directories
What they invest in
from 34 of 35 portfolio companiesBiotech ×32Healthtech ×22Medical Devices ×13AI & Machine Learning ×4Deep Tech ×4Digital Health ×4Energy ×1Enterprise Software ×1
HQs:United States×22United Kingdom×1
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×62 founders×24+ founders×1
Investments · 35 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 22023 · 12022 · 12021 · 52020 · 12019 · 12018 · 113 dated
Apogee Therapeutics develops engineered antibody therapies to treat inflammatory and immune diseases with reduced injection frequency compared to existing treatments.
BiotechHealthtechMedical Devices
Michael Henderson(Chief Executive Officer and Director)in
Co-investorsRA CapitalWellington ManagementBlackstone Life SciencesPerceptive Xontogeny VentureRTW Investments L.P.Venrock Healthcare Capital Partners
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)inManuel Litchman(Executive Officer, Director)inRandy Teel(President and Chief Executive Officer; Director)inCraig Crews(Founder)
BoardStephen Squinto(Director)inLiam Ratcliffe(Director)in
Co-investors5AM VenturesCanaan PartnersConnecticut InnovationsNextech InvestRA CapitalSolasta Ventures+2 more
Damora Therapeutics is a preclinical-stage biotechnology company that discovers and develops therapeutic candidates, including DMR-001, DMR-002, and DMR-003, with the goal of advancing treatments through investigational drug applications and clinical trials.
BiotechCopenhagen, US
Garrett Winslow(Executive Officer)inLori Firmani(Executive Officer)inHans T. Schambye(Executive Officer, Director)Jennifer Jarrett(President, Chief Executive Officer and Director)inBecker Hewes(Chief Medical Officer)Sherwin Sattarzadeh(Chief Operating Officer)
Co-investorsViking GlobalAndreessen HorowitzBAM ElevateBay City CapitalCommodore CapitalEIR Ventures+8 more
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)inJean Franchi(Chief Financial Officer)inJonathan Yu(Chief Operating Officer)inWill Savage(Chief Medical Officer)inPamela Stephenson(Chief Commercial Officer)inSteve Caffé(Chief Regulatory Officer)in
Co-investorsAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed5AM Ventures+7 more
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesACORN BIOVENTURESIntermediate Capital GroupLifeArc VenturesRA Capital
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsHealthCapNovo HoldingsSofinnova PartnersRA Capital
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies.
BiotechDigital HealthHealthtechMedical DevicesBoulder, US
Jason Leverone(Executive Officer)inSamuel Agresta(Executive Officer)inDylan Hartley(Executive Officer)inWendy Johnson(Executive Officer)Nicholas A. Saccomano(President and Chief Executive Officer and Director)
BoardIsaac Manke(Director)in
Co-investorsBoulder VenturesRiverVest Venture PartnersAbingworthACORN BIOVENTURESNew Enterprise Associates (NEA)Novo Holdings
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Co-investorsFrazier Life SciencesFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersOrbiMedSphera Funds Management+2 more
Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
BiotechHealthtechMedical Devices
Cameron Turtle(Chief Executive Officer and Director)in
Co-investorsAisling Capital
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesBain Capital Life SciencesDecheng CapitalHBM Healthcare InvestmentsHBM Partners+5 more
Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously.
BiotechHealthtechLa Jolla, US
Someit Sidhu(Executive Officer, Director)inMuzammil Mustufa(Chief Business Officer)inKiran Nistala(Chief Medical Officer and Head of Development)inNeil Graham(Director)Gary Whale(Chief Technology Officer)Garry Neil(Director)
Co-investorsTMG Ventures
Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.
BiotechDeep TechDigital HealthMedical DevicesCardiff, GB
John Atack(Head of Biology & Founder)inSimon Ward(Chief Scientific Officer & Founder)in
Co-investorsCanaan PartnersSanofi VenturesSV Health InvestorsSR One Capital ManagementBritish Business BankJanus Henderson Investors
Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)inNewman Yeilding(Chief Medical Officer)in
Co-investorsAndreessen HorowitzGV (Google Ventures)Versant VenturesRTW Investments L.P.TPGAccess Industries+1 more
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)inSchalon Newton(Executive Officer)in
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsExSight VenturesHatteras Venture PartnersSolasta VenturesBios PartnersCorrelation VenturesFemHealth Ventures+1 more
Areteia Therapeutics was a clinical-stage biotechnology company that is no longer operating.
BiotechChapel Hill, US
Robin Walker(Executive Officer)inChristopher Courts(Executive Officer)inJorge Bartolome(Founder)in
BoardBenjamin Gomez(Director)Adam Koppel(Director)inMichael E. Bozik(Director)
Co-investorsARCH Venture PartnersBain Capital Life SciencesGV (Google Ventures)Solas BioVenturesViking GlobalMaverick Capital+3 more
Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.
BiotechHealthtechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)
BoardMichael Gladstone(Director)inDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)inDaniel Becker(Director)
Co-investorsAtlas VentureCanaan PartnersViking GlobalAccess IndustriesRA CapitalThe Column Group
A pharmaceutical company developing treatments for serious chronic diseases with a focus on long-term health solutions and improving medicine access and affordability globally.
BiotechDigital HealthHealthtech
Co-investorsBain Capital Life SciencesRidgeback CapitalOxford Bioscience PartnersRA Capital
The page presented is corporate content for Novartis, a pharmaceutical company that develops medicines across areas such as multiple sclerosis, cardiovascular disease, and oncology.
BiotechHealthtechSan Diego, US
Arthur Suckow, Ph.D.(Founder)in
Co-investorsExSight VenturesRA CapitalJanus Henderson Investors
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)in
BoardTim Shannon(Manager)inLiam Ratcliffe(Manager)in
Co-investorsCanaan PartnersConnecticut InnovationsElm Street VenturesFrazier Life SciencesRA CapitalTaiho Ventures, LLC+1 more
Khanda is a biotech company builder that translates validated and emerging biological insights into new biotechnology companies focused on orthogonal, combination-based therapeutic approaches.
Biotech
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.
BiotechHealthtechMedical DevicesThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)Sean Harper Desmond Padhi(Founder)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)inDeborah Palestrant(Director)in
Co-investors5AM VenturesAscenta CapitalForesite CapitalKern Capital, LLCSanofi VenturesWestlake Village BioPartners
Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureNextech InvestAccess IndustriesForbionRA Capital
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
BiotechCambridge, US
Andre Turenne(Executive Officer, Director)in
BoardJason Hafler(Director)inBruce Booth(Director)Daniel Becker(Director)
Co-investorsDigitalis VenturesSanofi VenturesAccess IndustriesAlexandriaAtlas Venture
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAtlas VentureBain Capital Life SciencesBiotechnology Value FundCommodore CapitalGV (Google Ventures)+2 more
FuseBase is an enterprise platform for deploying and managing AI agents across teams with role-based access controls, audit trails, and integrations to CRM, Slack, Teams, and email systems.
AI & Machine LearningEnterprise SoftwareFuture of WorkSaaSCleveland, US
Pavel Sher(CEO)Aaron Adsit(CRO)Denis Kibalko(CTO)
Co-investorsPre-Seed to SucceedYellow Rocks!Atlas VentureBain Capital Life SciencesBiotechnology Value FundCommodore Capital+3 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Lightstone VenturesPfizer Venture Investments+4 more
Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.
BiotechCambridge, US
Jo Viney(Executive Officer)Rahul Kakkar(Executive Officer, Director)inAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)
Co-investorsJDRF T1D FundMission BiocapitalRA CapitalSR One Capital ManagementPolaris PartnersVersant Ventures
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)Chau Khuong(Director)in
Co-investorsOrbiMedCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesHatteras
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)in
BoardPETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsMission BiocapitalSofinnova VenturesSR One Capital ManagementMission Bay CapitalNew Leaf Venture PartnersOrbiMed+1 more
Recludix Pharma operates a drug discovery platform that combines custom DNA-encoded libraries (DELs), massively parallel structure-activity relationship analysis, structure-based design, and a family-wide SH2 domain screening panel.
AI & Machine LearningBiotechDeep TechHealthtechSan Diego, US
Nancy Whiting(CEO)in
Co-investorsNew Enterprise Associates (NEA)Westlake Village BioPartners
Surrozen develops multifunctional biologic therapies that selectively activate Wnt signaling to address ophthalmic diseases with unmet medical needs.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Anna Berkenblit(Director)Harold Varmus(Director)
BoardDavid Goeddel(Director)inCraig Parker(Executive Officer, Director)Tim Kutzkey(Director)in
Co-investors5AM VenturesThe Column GroupHorizons Ventures
Verona Pharma develops treatments for chronic lung conditions.
BiotechHealthtechLondon
Jan-Anders Karlsson(Executive Officer, Director)inPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)
Co-investorsAisling CapitalAndera PartnersForesite CapitalFrazier Life SciencesNew Enterprise Associates (NEA)Sofinnova Partners+4 more
Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.
BiotechHealthtechMedical Devices
Bernard Ravina(Founder and Chief Executive Officer)inJudy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)inAriel D. Jasie(Chief Business Officer and General Counsel)inTushar Misra(Chief Technical Officer)in
Co-investorsAtlas VentureFrazier Life SciencesAccess IndustriesCanaan Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Dice
Exits · 13
11 IPOs · 2 acquisitionsApogee TherapeuticsNASDAQ: APGEArvinas Holding Co. LLCNASDAQ: ARVNDamora TherapeuticsNASDAQ: DMRADisc MedicineNASDAQ: IRONEliem TherapeuticsNASDAQ: CLYMHemab TherapeuticsNASDAQ: COAGOnkure Therapeutics IncNASDAQ: OKURPassage BioNASDAQ: PASGSpyre TherapeuticsNASDAQ: SYREUpstream BioNASDAQ: UPBZura BioNASDAQ: ZURADTx Pharmaacq. by NovartisPandion Therapeuticsacq. by Merck
Portfolio news
latest coverage across their companiesDraig Therapeutics · finsmes.com · Jul 14, 2026
Talawar · stocktitan.net · Jun 29, 2026
Recludix · recludixpharma.com · Jan 12, 2026
Frequently asked questions
- How many investments has Access Biotechnology made?
- Access Biotechnology has 35 tracked investments, 13 of which have exited, including 1 dated in the last 24 months.
- What stage does Access Biotechnology invest at?
- Access Biotechnology invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Access Biotechnology focus on?
- Access Biotechnology focuses on Biotech, Healthtech, Medical Devices.
- Where is Access Biotechnology located?
- Access Biotechnology is headquartered in New York, US.
- Does Access Biotechnology lead rounds?
- Yes, Access Biotechnology leads investment rounds.
- Who does Access Biotechnology co-invest with?
- Access Biotechnology most often shares deals with RA Capital, Atlas Venture, Canaan Partners, among 55 tracked co-investors.
Images
Co-investors · 5
Access Industries is a private holding company and global investment firm founded in 1986 by Len Blavatnik that identifies companies with strong business models and management teams to optimize their value through financial backing and strategic expertise.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Amzak Health is a venture investor focused on first-in-class and best-in-class technologies in the medtech and biotech sectors, partnering closely with portfolio company management teams.
Firms observed investing alongside Access Biotechnology, from public investor directories. Shared companies are the overlap with Access Biotechnology's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
Norwest is a venture capital and growth equity investment firm that has backed over 700 companies across technology, consumer, and healthcare over its 65-year history.